Revenue declined 5.6% year-over-year due to lower lenalidomide sales and a semaglutide provision, but base business showed double-digit growth across geographies. EBITDA margin was 12.5%, with guidance maintained near 20% as semaglutide supplies are expected to resume in November. Strong launches and robust growth in India and emerging markets offset challenges.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.